Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC This drug was developed by Eli Lilly & Company.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
ATC prefix |
|
c |
|
CAS number |
|
ChemSpiderID |
|
H |
|
n |
|
O |
|
s |
|
source |
|
synonyms |
|
target | |
type |
|
UNII |
|
has abstract |
|
IUPHAR ligand |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
FDA UNII code |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is foaf:primaryTopic of |